瑞普生物：公司对未来原料药行情的走势保持谨慎乐观

Core Viewpoint - The company has significantly improved its raw material drug segment's operating conditions, with a gross margin increase of over 10 percentage points year-on-year, leading to a notable reduction in losses [1] Group 1: Financial Performance - The raw material drug segment's operating conditions have improved significantly this year due to optimized product structure and internal management [1] - The gross margin for the raw material drug segment has increased by more than 10 percentage points compared to the previous year [1] - The company has achieved a significant reduction in losses within this segment [1] Group 2: Future Outlook and Strategies - The company maintains a cautiously optimistic outlook on the future trends of the raw material drug market [1] - Plans to continue enhancing the quality and reducing costs in the raw material drug segment include: - Deepening lean cost reduction through precise diagnosis and optimization of production processes and strengthening centralized procurement management to effectively lower unit production costs [1] - Accelerating overseas market expansion to continue increasing export share [1] - Optimizing product structure to increase the proportion of high-margin products and further enrich the high value-added product matrix to improve overall profitability [1]